- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03077659
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy
Study Overview
Detailed Description
In this open-label, dose rising, Phase IIa trial with an expanded cohort at the dose of NanoPac® determined to have the best tolerability and safety profile, subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy. The study will include a dose escalation phase and a dose confirmation phase.
In the dose escalation phase, NanoPac® concentrations of 6, 10, and 15 mg/mL in an injection volume of 20% of the lobe of the prostate containing the dominant lesion will be studied in cohorts of 3, with cohorts enrolled sequentially starting at the lowest concentration. Following DSMB review of the cohort data the next cohort may begin enrolling, or an additional 3 at the current dose may be enrolled, or if the first dose does not provide adequate safety and tolerability the study may be halted. The dose determined to be the most suitable for further evaluation, defined as the highest dose with an acceptable safety and tolerability profile as determined by the DSMB, will enroll additional subjects to provide a cohort of 12 subjects at that dose level.
Tumor volume and serum prostate-specific antigen (PSA) will be determined prior to NanoPac® injection. Pharmacokinetic samples, PSA, and ejaculate will be collected in the interval between injection and prostatectomy. Imaging with mpMRI will be performed prior to NanoPac® injection and prior to prostatectomy. Prostate and pelvic lymph nodes excised at prostatectomy will be evaluated.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male; 18 years of age and older
- Histopathologically proven adenocarcinoma, Gleason grade ≥ 7 of the prostate planned radical prostatectomy; appropriate for treatment with paclitaxel therapy
- ECOG of 0 or 1
Laboratory requirements:
- WBC >2500/mm3
- Neutrophil >1500/mm3
- Hemoglobin >10 mg/dL
- Platelet >100,000/ mm3
- AST and ALT <2.5 x ULN
- Total bilirubin <1.5 x ULN
- Creatinine <2 mg/dL
- Normal PT/INR and PTT;
- Willing to use appropriate contraception from time of NanoPac® injection until prostatectomy
- Willing to receive an mpMRI
Exclusion Criteria:
- Evidence of locally advanced or metastatic disease;
- Prostate size ≥ 50 cc
- Prior prostatectomy
- Anticipated use of concomitant chemotherapy (other than the protocol specified agents), immunotherapy, or systemic use of hormonal therapy (such as GnRH analogs, antiandrogens, androgen receptor inhibitors, and 5-α reductase inhibitors) prior to surgery
- Treatment with a prior investigational agent within 30 days of first dose of investigational medication
- Any previous local treatment of the prostate (i.e. radiation)
- Any other condition (e.g. psychiatric disorder) that, in the opinion of the Investigator, may interfere with the patient's ability to comply with the study requirements or visit schedule
- Known sensitivity to any of the study medication components
- History of prior malignancy that has not been in remission for >5 years, with the exception of basal cell or squamous cell carcinoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: NanoPac® 6 mg/mL
NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
|
Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
Other Names:
|
EXPERIMENTAL: NanoPac® 10 mg/mL
NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
|
Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
Other Names:
|
EXPERIMENTAL: NanoPac® 15 mg/mL
NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
|
Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
Time Frame: Day 1 to Day 29
|
Treatment Emergent Adverse Events included laboratory assessments, physical examination findings, and vital signs.
|
Day 1 to Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response Based on Change in Image Volume on mpMRI
Time Frame: Up to three months prior to consent and Day 29
|
Tumor response to treatment with NanoPac was determined by evaluating the change in image volume with multiparametric MRI (mpMRI) within three months prior to consent and again within 48 hours of the prostatectomy procedure (Day 29).
In those cases where two dimensions/axes were available, width was imputed to height for the purposes of calculation, i.e. the lesion was assumed to be an oblate spheroid.
In those cases where only one dimension/axis was available, that dimension/axis was imputed for all three dimensions i.e. the lesion was assumed to be a sphere.
For this reason, analyses were performed for all subjects with two dimensions available, as well as those for which at least one dimension was available.
The data presented for this outcome measure is the one dimension lesion volume calculation: Lesion Volume (cc) = (3.14/6)*(length)³,
where length is the longer or only measured dimension.
|
Up to three months prior to consent and Day 29
|
Tumor Response Based on Histologic Evaluation of Biopsied Prostate Samples (Gleason Score)
Time Frame: Screening and Day 29
|
Prostate tissue samples were obtained via biopsy at baseline and immediately prior to prostatectomy (Day 29).
Histologic evaluation of these samples was used to determine the Gleason score, and the results at baseline and Day 29 were used to evaluate the tumor response to treatment with NanoPac®.
The Gleason score is calculated by adding together the two grades of cancer cells that make up the largest areas of the biopsied tissue sample.
The Gleason score usually ranges from 6 to 10.
The lower the Gleason score, the more the cancer cells look like normal cells and are likely to grow and spread slowly; a higher Gleason score is likely to indicate a worse outcome.
The Gleason score is used to help plan treatment and determine prognosis.
|
Screening and Day 29
|
Percentage of Sample Considered Adenocarcinoma
Time Frame: Day 29 (prostatectomy)
|
Tissues excised from the primary tumor during prostatectomy (Day 29) were evaluated for the percentage considered adenocarcinoma
|
Day 29 (prostatectomy)
|
Concentration of Paclitaxel in the Systemic Circulation
Time Frame: Day 1, Day 8, Day 15, Day 22, and Day 29
|
Pharmacokinetic samples were taken on Day 1 at 1, 2, 4, and 6 hours post-injection, and weekly until prostatectomy.
All numeric paclitaxel concentration data above the Lower Limit of Quantitation (25 pg/mL) was tabulated by cohort.
|
Day 1, Day 8, Day 15, Day 22, and Day 29
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NANOPAC-2016-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Prostate
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
Dana-Farber Cancer InstituteCompletedProstate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
Sir Mortimer B. Davis - Jewish General HospitalAbbottRecruitingAdjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma ProstateAdenocarcinoma of the ProstateCanada
-
Virginia Commonwealth UniversityCompletedAdenocarcinoma of the ProstateUnited States
-
Centre Georges Francois LeclercActive, not recruiting
-
University Hospital, BrestRecruitingAdenocarcinoma of the ProstateFrance
-
University of California, DavisCompletedAdenocarcinoma of the ProstateUnited States
-
Centre Hospitalier Universitaire de NīmesActive, not recruitingAdenocarcinoma of the ProstateFrance
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedAdenocarcinoma of the ProstateUnited States
-
James TaylorCompleted
Clinical Trials on NanoPac®
-
NanOlogy, LLCUS Biotest, Inc.TerminatedOvarian CarcinomaUnited States
-
NanOlogy, LLCUS Biotest, Inc.CompletedPancreatic Mucinous-Cystic NeoplasmUnited States
-
NanOlogy, LLCUS Biotest, Inc.CompletedLocally Advanced Pancreatic AdenocarcinomaUnited States
-
NanOlogy, LLCUS Biotest, Inc.Active, not recruitingLung Cancer | Lung Cancer, Nonsmall Cell | Neoplasm of Lung | Lung Cancer, Small CellUnited States
-
NanOlogy, LLCUS Biotest, Inc.TerminatedUrogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer AdenocarcinomaUnited States
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States